Innovative Delivery Platform Biora's development of the BioJet Oral Delivery Platform offers a groundbreaking needle-free alternative for complex molecule delivery, presenting a significant opportunity to partner with pharmaceutical companies seeking patient-friendly drug administration solutions.

Recent Funding Growth With recent financing rounds totaling over 7 million dollars and ongoing capital raises, Biora is positioned for accelerated R&D collaborations and clinical trials, making it a compelling partner for investors and collaborators aiming to advance innovative therapeutic technologies.

Strategic Industry Engagement Participation in prominent industry events like the Annual PODD meeting and receiving awards such as the Presidential Poster Award indicate a strong reputation and visibility within the drug delivery sector, increasing opportunities for strategic partnerships and licensing deals.

Small but Focused Team With a lean team of up to 50 employees, Biora is agile and innovative, offering personalized collaboration and flexible partnership models to large pharma entities interested in integrating novel oral delivery systems into their pipeline.

Market Expansion Potential Targeting large pharmaceutical companies with high-revenue portfolios, Biora's technology aligns with current market trends favoring patient-centric, needle-free therapies, creating opportunities for licensing, co-development, and commercialization agreements.